OS Therapies announces $6M private placement; OST-HER2 Phase 2b data in Jan 2025

OS Therapies Inc

Gross proceeds of $6M from sale of 1.5M units at $4.00/unit; each unit = 1 share Series A convertible preferred + 1 warrant.
Initial conversion price $4.00, warrant exercise price $4.40; prices subject to reset with floor of $1.00 and ceiling $4.00.
Proceeds to fund working capital and support commercialization of OST-HER2 for recurrent metastatic osteosarcoma.
Phase 2b trial data for OST-HER2 expected during week of JP Morgan Healthcare Conference in January 2025.
95% of investment from pre-IPO and/or IPO investors; $6M provides cash runway into 2026.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OS Therapies Inc: Filed Certificate of Designation establishing Series A Senior Convertible Preferred Stock rights, preferences, and limitations (effective 2024-12-27).

Change: charter amendment
Effective: 2024-12-27

Exact text from the filing

On December 27, 2024, the Company, in accordance with Section 151(g) of the Delaware General Corporation Law, filed a Certificate of Designation, Preferences, Rights and Limitations of Series A Senior Convertible Preferred Stock

View on SEC.gov

Browse all governance changes →

OS Therapies Inc filing history →

Source: SEC EDGAR

accession 0001213900-24-113561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.